Search Results for: lilly

EVOX THERAPEUTICS ANNOUNCES A MULTI-TARGET RNA INTERFERENCE AND ANTISENSE RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH LILLY

by

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox’s proprietary DeliverEXTM platform to develop … Read more

Pipeline

by

Focus on Rare Diseases Utilising the DeliverEX® platform, Evox is developing a pipeline of drugs leveraging the exosome’s unique ability to deliver drugs to cells and tissues that are currently inaccessible by conventional means. Exosomes are nano-sized vesicles and present a safe and potent modality for precision delivery of advanced payloads, including AAV vectors, genome … Read more

EVOX THERAPEUTICS WINS BEST EMERGING BIOTECH AT THE OBN AWARDS CEREMONY IN LONDON

by

Accolade recognises Evox’s efforts in developing a proprietary pipeline of exciting therapeutics based on exosome technology, a successful fundraising and transformative deals with Takeda and Eli Lilly Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that it has been awarded the Best Emerging Biotech Award at the … Read more

EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCING

by

Financing round significantly oversubscribed by both new and existing investors Proceeds enable advancement of our exosome therapeutics into the clinic and expansion of our world-leading exosome platform Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round. … Read more